| Literature DB >> 20528533 |
Abstract
Evidence based medicine is not only important for clinical practice, but national governments have embraced it through health technology assessment (HTA). HTA combines data from randomized controlled trials (RCT) and observational studies with an economic component (among other issues). HTA, however, is not taking full advantage of economics. This paper presents five areas in which economics may improve not only HTA, but the RCT methods that underpin it. HTA needs to live up to its original agenda of being a interdisciplinary field and draw methods not just from biostatistics, but from a range of discipline, including economics. By focusing only on cost effectiveness analysis (CEA), however, we go nowhere close to fulfilling this potential.Year: 2006 PMID： 20528533 DOI： 10.1586/14737167.6.1.19
Source DB: PubMed Journal: Expert Rev Pharmacoecon Outcomes Res ISSN： 1473-7167 Impact factor: 2.217